Long-term Analysis of Epi-ON Corneal Collagen Cross-linking Outcomes in Corneal Ectasia
Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10045/118705
Título: | Long-term Analysis of Epi-ON Corneal Collagen Cross-linking Outcomes in Corneal Ectasia |
---|---|
Autor/es: | Melián, Rafael | Rodriguez, Vicente | Carreras, Humberto | Piñero, David P. | Gonzalez-Martín, Jesús M. | Galván, Francisco |
Grupo/s de investigación o GITE: | Grupo de Óptica y Percepción Visual (GOPV) |
Centro, Departamento o Servicio: | Universidad de Alicante. Departamento de Óptica, Farmacología y Anatomía |
Palabras clave: | Corneal collagen cross-linking | Corneal ectasia | Corneal tomography | Keratoconus | Pellucid marginal degeneration | Post-LASIK ectasia |
Área/s de conocimiento: | Óptica |
Fecha de publicación: | 2021 |
Editor: | Jaypee Brothers Medical Publishers |
Cita bibliográfica: | Melián R, Rodriguez V, Carreras H, et al. Long-term Analysis of Epi-ON Corneal Collagen Cross-linking Outcomes in Corneal Ectasia. Int J Kerat Ect Cor Dis 2021. https://doi.org/10.5005/jp-journals-10025-1187 |
Resumen: | Purpose: To evaluate the 3-year follow-up clinical outcomes obtained in corneal ectasia using Epi-ON corneal collagen cross-linking (CXL). Methods: This study is a retrospective study enrolling 46 eyes from 32 patients with progressive corneal ectasia and treated with Epi-ON CXL in the period from September 2012 to April 2016. Two groups were differentiated according to the type of corneal ectasia: ectasia post-LASIK group (EPL, 12 eyes) and primary ectasia group (34 eyes). Two different platforms were used for the surgical protocol: VEGA CBM X LINKER platform (CSO, Firenze, Italy) and KXL (Avedro, Waltham, Massachusetts, USA). Visual, refractive, and corneal tomographic outcomes were evaluated during a 3-year follow-up. Results: A statistically significant improvement in the logMAR corrected distance visual acuity (CDVA) was observed in the whole sample (p <0.001) during the follow-up, with half of the sample improving one or more lines of CDVA. Likewise, only significant changes were detected in steepest keratometry (p <0.001), corneal astigmatism (p = 0.012), and index of height asymmetry (p = 0.021), with a trend to increase. Regarding the comparison between groups, more significant improvement in CDVA was found in the EPL group compared to the primary ectasia group (−0.07 ± 0.09 vs −0.15 ± 0.14, p = 0.028). Likewise, a significant trend to more corneal thinning was observed in primary ectasia group (p = 0.034). Conclusion: Epi-ON CXL is efficacious for stabilizing the progression of primary and iatrogenic ectasias for most cases, with significant improvement of visual acuity associated. |
Patrocinador/es: | The author David P Piñero has been supported by the Ministry of Economy, Industry and Competitiveness of Spain within the program Ramón y Cajal, RYC-2016-20471. |
URI: | http://hdl.handle.net/10045/118705 |
ISSN: | 2277-3800 (Print) | 2277-4203 (Online) |
DOI: | 10.5005/jp-journals-10025-1187 |
Idioma: | eng |
Tipo: | info:eu-repo/semantics/article |
Derechos: | © The Author(s). 2021 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons. org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
Revisión científica: | si |
Versión del editor: | https://doi.org/10.5005/jp-journals-10025-1187 |
Aparece en las colecciones: | INV - GOPV - Artículos de Revistas |
Archivos en este ítem:
Archivo | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Melian_etal_2021_IntJKeratEctCornDis.pdf | 466,71 kB | Adobe PDF | Abrir Vista previa | |
Este ítem está licenciado bajo Licencia Creative Commons